A panel of internationally recognized research scientists and
clinical investigators brings together a diverse collection of
readily reproducible methods for identifying and quantifying a
large number of specific genetic abnormalities associated with the
broad spectrum of myeloid malignancies. Highlights include
techniques for the detection of BCR-ABL mutations and resistance to
imatinib mesylate, detection of the FIP1L1-PDGFRA fusion in
idiopathic hypereosinophilic syndrome and chronic eosinophilic
leukemia, classification of AML by DNA-oligonucleotide microarrays,
and detection of the V617F JAK2 mutation in myeloproliferative
disorders. In addition to gene rearrangments, other prognostically
relevant molecular lesions such as FLT3 mutations and WT-1
overexpression are covered.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!